

CURRICULUM VITAE

■ Professional Address :

Eric Baudin
Service d'Oncologie Endocrinienne
Institut Gustave Roussy
94805 Villejuif Cedex

Council N°94/10542
RPPS 1000 114 6413
SIRET 775 74 11 01
ADELI 94 11 054 21

■ EDUCATION/TRAINING

- 1987 Degree as Advanced Studies of Biotechnology/Laboratory research, University Paris VI; Paris, France
- 1988 Degree as Medical Doctor (MD); University Paris XIII; Paris, France
- 1991 Specialized post-graduate degree in Endocrinology; University Paris VII; Paris, France
- 1993 Specialized post-graduate degree in Nuclear Medicine; University Paris XI Paris, France
- 1997 Specialized post-graduate degree in Oncology; University Paris XI Paris, France
- 2008 PhD in Oncology, Biology, Medicine and Health; University Paris XI Paris, France
- 2013 HDR, University Paris XI Paris, France

■ PROFESSIONAL EXPERIENCE

- 1979-86 Medical student, University Paris VI; Paris, France
- Intern in medicine, Paris : 1986- 1991
- Residency in Nuclear Medicine- Institut Gustave-ROUSSY (GR): 1991-1992:
- Chef de Clinique-Assistant des Hôpitaux de Paris :1992- 1995
- Residency in Nuclear Medicine - GR : 1995- 1996
- Full time equivalent assistant endocrine oncology - GR : 1996- 1999
- Assistant-professor in Endocrine Oncology - GR : 2000 – present time

■ EXPERIENCE IN CLINICAL RESEARCH

- As PI ,including FIRSTMAPPP, OCLURANDOM, LUNA, SPINET or, SI for many clinical trials since 2010 years
- Currently principal investigator or sub-investigator for more than 30 clinical trials
- Last training in “Good clinical practice and regulatory requirements for clinical trial” validated 26 June 2021

■ ORGANIZATIONS

- Head of the endocrine tumor board , Gustave ROUSSY: 2010-present time
- ENSAT Executive comitee
- Head of the COMETE network 2009-2019
- Head of the RENATEN network 2017-2020
- President of the French Group of Endocrine Tumors (GTE) : 2016-2019
- ERN expert centres for endocrine and neuroendocrine tumors : 2016-present time
- Head of the ENDOCAN endocrine network 2019-2023
- ESMO secretary for Endocrine Tumors 2019-2021
- ENETS executive comitee member 2020-2023

■ REFERENCES

>300 publications, h-index of 72, number of citations higher than 22977 ; including :

- Combination chemotherapy in advanced adrenocortical carcinoma. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B, Sorbye H, Torpy DJ, Stepan V, Scheingart DE, Arlt W, Kroiss M, Leboulleux S, Sperone P, Sundin A, Hermsen I, Hahner S, Willenberg HS, Tabarin A, Quinkler M, de la Fouchardière C, Schlumberger M, Mantero F, Weismann D, Beuschlein F, Gelderblom H, Wilmink H, Sender M, Edgerly M, Kenn W, Fojo T, Müller HH, Skogseid B; FIRM-ACT Study Group. *N Engl J Med.* 2012 Jun 7;366(23):2189-97.
- Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, Klimovsky J, Lewohl D, Jehl V, Wolin EM, Öberg K, Van Cutsem E, Yao JC; RADIANT-2 Study Group. *Lancet.* 2011 Dec 10;378(9808):2005-2012.
- New therapeutic approaches for metastatic thyroid carcinoma. Baudin E, Schlumberger M. *Lancet Oncol.* 2007 Feb;8(2):148-56.
- Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, Kroiss M, Quinn DI, Hesseltine E, Ronchi CL, Terzolo M, Choueiri TK, Poondru S, Fleege T, Rorig R, Chen J, Stephens AW, Worden F, Hammer GD. *Lancet Oncol.* 2015 Apr;16(4):426-35.
- Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial. Ferolla P, Brizzi MP, Meyer T, Mansoor W, Mazieres J, Do Cao C, Léna H, Berruti A, Damiano V, Buikhuisen W, Grønbaek H, Lombard-Bohas C, Grohé C, Minotti V, Tiseo M, De Castro J, Reed N, Gislumberti G, Singh N, Stankovic M, Öberg K, Baudin E. *Lancet Oncol.* 2017 Dec;18(12):1652-1664.
- Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study. Castinetti F, Waguespack SG, Machens A, Uchino S, Hasse-Lazar K, Sanso G, Else T, Dvorakova S, Qi XP, Elisei R, Maia AL, Glod J, Lourenço DM Jr, Valdes N, Mathiesen J, Wohllk N, Bandgar TR, Drui D, Korbonits M, Druce MR, Brain C, Kurzawinski T, Patocs A, Bugalho MJ, Lacroix A, Caron P, Fainstein-Day P, Borson Chazot F, Klein M, Links TP, Letizia C, Fugazzola L, Chabre O, Canu L, Cohen R, Tabarin A, Spehar Uroic A, Maiter D, Laboureau S, Mian C, Peczkowska M, Sebag F, Brue T, Mirebeau-Prunier D, Leclerc L, Bausch B, Berdelou A, Sukurai A, Vlcek P, Krajewska J, Barontini M, Vaz Ferreira Vargas C, Valerio L, Ceolin L, Akshintala S, Hoff A, Godballe C, Jarzab B, Jimenez C, Eng C, Imai T, Schlumberger M, Grubbs E, Dralle H, Neumann HP, Baudin E. *Lancet Diabetes Endocrinol.* 2019 Mar;7(3):213-220.
- Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. Dromain C, de Baere T, Lumbroso J, Caillet H, Laplanche A, Boige V, Ducreux M, Duvillard P, Elias D, Schlumberger M, Sigal R, Baudin E. *J Clin Oncol.* 2005 Jan 1;23(1):70-8.
- Characterization, Prognosis, and Treatment of Patients With Metastatic Lung Carcinoid Tumors. Robelin P, Hadoux J, Forestier J, Planchard D, Hervieu V, Berdelou A, Scoazec JY, Valette PJ, Leboulleux S, Ducreux M, Lombard-Bohas C, Baudin E, Walter T. *J Thorac Oncol.* 2019 Jun;14(6):993-1002.
- Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruzsniwski P, Hoosen S, St Peter J, Haas T, Lewohl D, Van Cutsem E, Kulke MH, Hobday TJ, O'Dorisio TM, Shah MH, Cadiot G, Luppi G, Posey JA, Wiedenmann B. *J Clin Oncol.* 2010 Jan 1;28(1):69-76
- Genetic testing in pheochromocytoma or functional paraganglioma. Amar L, Bertherat J, Baudin E, Ajzenberg C, Bressac-de Paillerets B, Chabre O, Chamontin B, Delemer B, Giraud S, Murat A, Niccoli-Sire P, Richard S, Rohmer V, Sadoul JL, Strompf L, Schlumberger M, Bertagna X, Plouin PF, Jeunemaitre X, Gimenez-Roqueplo AP. *J Clin Oncol.* 2005 Dec 1;23(34):8812-8.

Le 7 Juillet 2022

